Biodexa Announces Pricing of $10 Million Public Offering

Core Viewpoint - Biodexa Pharmaceuticals PLC has announced a public offering priced at $10 million, aimed at funding its development programs and general corporate purposes [2][3]. Offering Details - The offering consists of 157,000 ADS Units, each comprising one American depositary share (representing 100,000 ordinary shares) and two Series L warrants [2]. - Additionally, there are 2,891,781 Pre-Funded Units, each consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants [2]. - The public offering price for each ADS Unit is set at $3.28, while each Pre-Funded Unit is priced at $3.2799 [2]. Financial Proceeds - The expected gross proceeds from the offering, before deducting fees and expenses, are approximately $10 million [3]. - The net proceeds will be utilized for development programs, working capital, and other corporate purposes [3]. Closing and Agent Information - The offering is anticipated to close on December 19, 2025, pending customary closing conditions [4]. - Maxim Group LLC is acting as the sole placement agent for this offering [4]. Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7]. Product Details - eRapa is an oral formulation of rapamycin, an mTOR inhibitor involved in cellular metabolism and tumorigenesis [8]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential for glycaemic control in diabetes [9]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier [10][11].